Search

Objective: The aims of this study were to test the individual association of the serotonin transporter gene (SLC6A4), the brain-derived neurotrophic factor gene (BDNF) and the GABA(A) α(6) receptor subunit gene (GABRA6) with anxiety-related traits and to explore putative gene-gene interactions in a Spanish healthy sample., Method: A sample of 937 individuals from the general population completed the Temperament and Character Inventory questionnaire to explore Harm Avoidance (HA) dimension; a subsample of 553 individuals also filled in the Big Five Questionnaire to explore the Neuroticism dimension. The whole sample was genotyped for the 5-HTTLPR polymorphism (SLC6A4 gene), the Val66Met polymorphism (BDNF gene) and the T1521C polymorphism (GABRA6 gene)., Results: Homozygous individuals for the T allele of the T1512C polymorphism presented slightly higher scores for HA than C allele carriers (F = 2.96, P = 0.019). In addition, there was a significant gene-gene interaction on HA between the 5-HTTLPR and Val66Met polymorphisms (F = 3.4, P = 0.009)., Conclusion: GABRA6 emerges as a candidate gene involved in the variability of HA. The effect of a significant gene-gene interaction between the SLC6A4 and BDNF genes on HA could explain part of the genetic basis underlying anxiety-related traits., (© 2011 John Wiley & Sons A/S.)

The main goal of this study was to offer data about the efficacy of virtual reality exposure (VRE) in the treatment of panic disorder with or without agoraphobia (PDA). The study was a between-subject design with three experimental conditions (VRE group, in vivo exposure [IVE] group and waiting-list [WL] group) and repeated measures (pre-treatment, post treatment and 12 month follow-up). The treatment programmes lasted 9 weekly sessions. Thirty-seven patients meeting DSM-IV criteria for PDA participated in this study. The improvement achieved using virtual exposure was superior to a WL condition and similar to that achieved using IVE. Our results support the efficacy of VRE in the treatment of PDA at short and long term. The advantages of VRE for the treatment of PDA regarding cost-benefit issues are described. Copyright © 2007 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]